RAB3A

Across TCGA pan-cancer cohorts, RAB3A mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RAB3A data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RAB3A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RAB3A expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where RAB3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.863	0.542	.006	39	view →
CCRCC	OS	Median	All	1.000	0.679	.013	5	view →
LUAD	DFS	Median	II,III,IV	0.233	0.748	.038	4	view →
PDAC	DFS	Tertile	III,IV	0.984	0.250	.024	3	view →
UCEC	OS	Tertile	All	0.904	1.000	.042	2	view →
GBM	DFS	Quartile	All	0.832	0.670	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RAB3A–HNSC (DFS)

Open the HNSC breakdown →